

James B Bussel

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3776884/james-b-bussel-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

339
papers

19,292
citations

69
h-index

135
g-index

363
ext. papers

22,043
ext. citations

5.5
avg. IF

6.96
L-index

#	Paper	IF	Citations
339	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. <i>Blood</i> , 2009 , 113, 2386-93	2.2	1651
338	International consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood</i> , 2010 , 115, 168-86	2.2	1392
337	Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. <i>Lancet, The</i> , 2008 , 371, 395-403	40	663
336	Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. <i>New England Journal of Medicine</i> , 2007 , 357, 2237-47	59.2	610
335	The ITP syndrome: pathogenic and clinical diversity. <i>Blood</i> , 2009 , 113, 6511-21	2.2	533
334	AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. <i>New England Journal of Medicine</i> , 2006 , 355, 1672-81	59.2	414
333	Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2009 , 373, 641-8	40	412
332	Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. <i>Lancet, The</i> , 2011 , 377, 393-402	40	383
331	Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. <i>Blood</i> , 2009 , 113, 2161-71	2.2	346
330	Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. <i>New England Journal of Medicine</i> , 1986 , 314, 1236-9	59.2	321
329	Antenatal treatment of neonatal alloimmune thrombocytopenia. <i>New England Journal of Medicine</i> , 1988 , 319, 1374-8	59.2	287
328	How I treat idiopathic thrombocytopenic purpura (ITP). <i>Blood</i> , 2005 , 106, 2244-51	2.2	285
327	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Advances</i> , 2019 , 3, 3780-3817	7.8	267
326	Intravenous Anti-D Treatment of Immune Thrombocytopenic Purpura: Experience in 272 Patients. <i>Blood</i> , 1997 , 89, 2689-2700	2.2	265
325	The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2004 , 125, 232-9	4.5	238
324	Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. <i>Blood</i> , 2013 , 121, 537-45	2.2	236
323	Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. <i>Blood</i> , 2012 , 119, 5989-95	2.2	230

322	Fetal alloimmune thrombocytopenia. <i>New England Journal of Medicine</i> , 1997 , 337, 22-6	59.2	225
321	Effects of eradication of <i>Helicobacter pylori</i> infection in patients with immune thrombocytopenic purpura: a systematic review. <i>Blood</i> , 2009 , 113, 1231-40	2.2	210
320	Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. <i>Blood</i> , 2010 , 116, 4639-45	2.2	207
319	The pathogenesis of immune thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2006 , 133, 364-74	4.5	201
318	Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. <i>Blood</i> , 2009 , 113, 3154-60	2.2	186
317	Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. <i>Blood</i> , 2006 , 107, 2639-42	2.2	183
316	Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. <i>American Journal of Hematology</i> , 2021 , 96, 534-537	7.1	183
315	Estimation of the risk of thrombocytopenia in the offspring of pregnant women with presumed immune thrombocytopenic purpura. <i>New England Journal of Medicine</i> , 1990 , 323, 229-35	59.2	182
314	Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. <i>Blood</i> , 2008 , 112, 1325-8	2.2	181
313	Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. <i>British Journal of Haematology</i> , 2013 , 161, 411-23	4.5	180
312	Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. <i>American Journal of Obstetrics and Gynecology</i> , 1996 , 174, 1414-23	6.4	175
311	Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. <i>American Journal of Hematology</i> , 2004 , 76, 205-13	7.1	169
310	A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. <i>Blood</i> , 2011 , 118, 28-36	2.2	168
309	How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. <i>Blood</i> , 2012 , 120, 960-9	2.2	165
308	Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. <i>Blood</i> , 2009 , 114, 4777-83	2.2	155
307	Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. <i>American Journal of Obstetrics and Gynecology</i> , 1995 , 172, 475-9	6.4	150
306	Hematologic toxicity of sodium valproate. <i>The American Journal of Pediatric Hematology/Oncology</i> , 2000 , 22, 62-5		148
305	Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. <i>Blood</i> , 2017 , 130, 2527-2536	2.2	147

304	Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. <i>Obstetrics and Gynecology</i> , 2006 , 107, 91-6	4.9	144
303	Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. <i>Journal of Allergy and Clinical Immunology</i> , 2007 , 120, 1178-85	11.5	137
302	Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. <i>American Journal of Hematology</i> , 2018 , 93, 921-930 ¹	7.1	131
301	Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. <i>Lancet, The</i> , 2015 , 386, 1649-58	4.0	129
300	Defective regulatory B-cell compartment in patients with immune thrombocytopenia. <i>Blood</i> , 2012 , 120, 3318-25	2.2	127
299	Does <i>Helicobacter pylori</i> initiate or perpetuate immune thrombocytopenic purpura?. <i>Blood</i> , 2004 , 103, 890-6	2.2	127
298	Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. <i>Blood</i> , 2013 , 121, 2596-606	2.2	126
297	Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). <i>American Journal of Hematology</i> , 2003 , 72, 94-8	7.1	124
296	Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. <i>Journal of Pediatrics</i> , 2005 , 146, 217-21	3.6	117
295	Thrombopoietin receptor agonists: ten years later. <i>Haematologica</i> , 2019 , 104, 1112-1123	6.6	116
294	Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. <i>Blood</i> , 2002 , 100, 1388-1398	2.2	115
293	Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. <i>Blood</i> , 2011 , 117, 5723-32	2.2	114
292	Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. <i>Lancet Haematology, the</i> , 2015 , 2, e315-25	14.6	112
291	The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. <i>British Journal of Haematology</i> , 2007 , 138, 245-8	4.5	112
290	Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2008 , 83, 150-4	7.1	110
289	Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. <i>Journal of Pediatric Hematology/Oncology</i> , 2003 , 25, 660-4	1.2	102
288	Intravenous use of gammaglobulin in the treatment of chronic immune thrombocytopenic purpura as a means to defer splenectomy. <i>Journal of Pediatrics</i> , 1983 , 103, 651-4	3.6	100
287	Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. <i>PLoS Genetics</i> , 2015 , 11, e1005262	6	99

286	Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2005 , 45, 176-83	3	97
285	A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2001 , 112, 1076-8	4.5	97
284	Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. <i>Lancet, The</i> , 2016 , 388, 45-54	40	96
283	Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders. <i>Blood</i> , 2014 , 124, e4-e10	2.2	93
282	Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?. <i>Blood</i> , 2002 , 99, 1922-7	2.2	79
281	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. <i>Blood</i> , 2014 , 123, 3887-94	2.2	78
280	Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. <i>Obstetrics and Gynecology</i> , 2011 , 118, 1157-1163	4.9	78
279	Current approaches to the evaluation and management of the fetus and neonate with immune thrombocytopenia. <i>Seminars in Perinatology</i> , 2009 , 33, 35-42	3.3	77
278	Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by Fcγ ₃ polymorphisms. <i>British Journal of Haematology</i> , 2004 , 124, 511-8	4.5	76
277	Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). <i>Blood</i> , 2007 , 110, 3526-31	2.2	75
276	Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates. <i>Blood Reviews</i> , 2008 , 22, 33-52	11.1	74
275	Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. <i>Blood</i> , 2015 , 126, 1367-78	2.2	71
274	Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. <i>American Journal of Obstetrics and Gynecology</i> , 2010 , 203, 135.e1-14	6.4	71
273	Anti-HPA-3A induces severe neonatal alloimmune thrombocytopenia. <i>Journal of Pediatrics</i> , 2001 , 138, 862-7	3.6	71
272	In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. <i>Blood</i> , 2012 , 119, 4066-72	2.2	70
271	Beyond the platelet count: immature platelet fraction and thromboelastometry correlate with bleeding in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2014 , 166, 592-600	4.5	69
270	Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. <i>Health and Quality of Life Outcomes</i> , 2008 , 6, 13	3	69
269	Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. <i>Haematologica</i> , 2017 , 102, 1192-1203	6.6	67

268	Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2006 , 81, 19-25	7.1	67
267	Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. <i>Blood</i> , 2017 , 129, 1538-1547	2.2	66
266	Fc receptor blockade and immune thrombocytopenic purpura. <i>Seminars in Hematology</i> , 2000 , 37, 261-6	4	66
265	Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. <i>Haematologica</i> , 2014 , 99, 937-44	6.6	65
264	Congenital and acquired thrombocytopenia. <i>Hematology American Society of Hematology Education Program</i> , 2004 , 2004, 390-406	3.1	61
263	Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. <i>Obstetrics and Gynecology</i> , 2007 , 110, 249-55	4.9	60
262	Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. <i>Haematologica</i> , 2014 , 99, 1264-71	6.6	58
261	Cytomegalovirus can make immune thrombocytopenic purpura refractory. <i>British Journal of Haematology</i> , 2009 , 146, 104-12	4.5	58
260	Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy. <i>British Journal of Haematology</i> , 2003 , 123, 142-6	4.5	58
259	Refractory immune thrombocytopenic purpura: current strategies for investigation and management. <i>British Journal of Haematology</i> , 2008 , 143, 16-26	4.5	57
258	Advances in the management of alloimmune thrombocytopenia. <i>British Journal of Haematology</i> , 2007 , 136, 366-78	4.5	57
257	Immune thrombocytopenic purpura. <i>Hematology/Oncology Clinics of North America</i> , 2007 , 21, 743-59, vii	3.1	56
256	Immune thrombocytopenic purpura in adults. <i>Current Opinion in Hematology</i> , 2007 , 14, 535-56	3.3	56
255	Antiplatelet antibody testing in thrombocytopenic pregnant women. <i>American Journal of Obstetrics and Gynecology</i> , 1996 , 174, 1014-8	6.4	54
254	Management of thrombocytopenia. <i>F1000prime Reports</i> , 2014 , 6, 45		53
253	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. <i>Haematologica</i> , 2014 , 99, 1387-94	6.6	52
252	Alloimmune thrombocytopenia: state of the art 2006. <i>American Journal of Obstetrics and Gynecology</i> , 2006 , 195, 907-13	6.4	52
251	Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). <i>Pediatric Blood and Cancer</i> , 2015 , 62, 208-213	3	51

250	Platelets: an update on diagnosis and management of thrombocytopenic disorders. <i>Hematology American Society of Hematology Education Program</i> , 2001 , 282-305	3.1	51
249	Fc receptor blockade and immune thrombocytopenic purpura. <i>Seminars in Hematology</i> , 2000 , 37, 261-266		51
248	A pilot study of rhIL-11 treatment of refractory ITP. <i>American Journal of Hematology</i> , 2001 , 66, 172-7	7.1	49
247	A heparin-like anticoagulant in an 8-month-old boy with acute monoblastic leukemia. <i>American Journal of Hematology</i> , 1984 , 16, 83-90	7.1	49
246	Alloimmune thrombocytopenia in the fetus and newborn. <i>Seminars in Thrombosis and Hemostasis</i> , 2001 , 27, 245-52	5.3	48
245	Repeated courses of rituximab in chronic ITP: Three different regimens. <i>American Journal of Hematology</i> , 2009 , 84, 661-5	7.1	46
244	Development of disease-specific health-related quality-of-life instruments for children with immune thrombocytopenic purpura and their parents. <i>Journal of Pediatric Hematology/Oncology</i> , 2003 , 25, 56-62	1.2	46
243	Evans Syndrome. <i>Journal of Pediatric Hematology/Oncology</i> , 1995 , 17, 290-295	1.2	46
242	Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). <i>British Journal of Haematology</i> , 2013 , 160, 538-46	4.5	45
241	A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. <i>Health and Quality of Life Outcomes</i> , 2007 , 5, 11	3	45
240	IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. <i>Thrombosis and Haemostasis</i> , 2004 , 91, 771-8	7	45
239	Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. <i>Journal of Pediatrics</i> , 2014 , 165, 600-5.e4	3.6	44
238	One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. <i>Pediatric Blood and Cancer</i> , 2009 , 52, 259-62	3	44
237	Treatment of immune thrombocytopenic purpura in adults. <i>Seminars in Hematology</i> , 2006 , 43, S3-10; discussion S18-9	4	40
236	Isolated thrombocytopenia in patients infected with HIV: treatment with intravenous gammaglobulin. <i>American Journal of Hematology</i> , 1988 , 28, 79-84	7.1	40
235	Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. <i>Blood</i> , 2020 , 135, 472-490	2.2	38
234	Fostamatinib for persistent/chronic adult immune thrombocytopenia. <i>Immunotherapy</i> , 2018 , 10, 9-25	3.8	37
233	Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. <i>American Journal of Hematology</i> , 2019 , 94, 546-553	7.1	37

232	IRAK-4 and MyD88 deficiencies impair IgM responses against T-independent bacterial antigens. <i>Blood</i> , 2014 , 124, 3561-71	2.2	36
231	Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV anti-D and to IV gammaglobulin predict response to subsequent splenectomy?. <i>American Journal of Hematology</i> , 2001 , 67, 27-33	7.1	36
230	Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). <i>Pediatric Blood and Cancer</i> , 2012 , 58, 395-8	3	33
229	Thrombopoietin-receptor agonists. <i>Current Opinion in Hematology</i> , 2012 , 19, 392-8	3.3	33
228	Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2017 , 92, 730-738	7.1	32
227	Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 52, 595-9	3.1	32
226	Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. <i>American Journal of Obstetrics and Gynecology</i> , 2001 , 185, 976-80	6.4	32
225	Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. <i>British Journal of Haematology</i> , 2019 , 185, 549-562	4.5	31
224	Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia. <i>American Journal of Hematology</i> , 2016 , 91, 907-11	7.1	31
223	Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. <i>Modern Pathology</i> , 2012 , 25, 65-74	9.8	30
222	Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. <i>British Journal of Haematology</i> , 2011 , 155, 248-55	4.5	29
221	Long-term effects of fetal and neonatal alloimmune thrombocytopenia and its antenatal treatment on the medical and developmental outcomes of affected children. <i>American Journal of Perinatology</i> , 2006 , 23, 487-92	3.3	28
220	Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective. <i>Haematologica</i> , 2010 , 95, 1807-11	6.6	28
219	Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. <i>Blood Advances</i> , 2020 , 4, 4136-4146	7.8	28
218	Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 146, 467-478	11.5	28
217	Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?. <i>Haematologica</i> , 2019 , 104, 1124-1135	6.6	27
216	Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia. <i>American Journal of Hematology</i> , 2014 , 89, E228-34	7.1	26
215	Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura. <i>Current Opinion in Pediatrics</i> , 2008 , 20, 8-16	3.2	26

214	Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	25
213	The fetal and neonatal consequences of maternal alloimmune thrombocytopenia. <i>Best Practice and Research: Clinical Haematology</i> , 1998 , 11, 391-408		24
212	Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. <i>American Journal of Hematology</i> , 2019 , 94, 741-750	7.1	23
211	Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. <i>American Journal of Hematology</i> , 2018 , 93, 882-888	7.1	23
210	The long-term impact of rituximab for childhood immune thrombocytopenia. <i>Current Rheumatology Reports</i> , 2010 , 12, 94-100	4.9	23
209	Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia. <i>Haematologica</i> , 2019 , 104, 2283-2291	6.6	22
208	Maternal HPA-1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review. <i>Vox Sanguinis</i> , 2019 , 114, 79-94	3.1	22
207	Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment. <i>American Journal of Hematology</i> , 2021 , 96, 188-198	7.1	22
206	Thrombopoietin receptor agonists: a critical review. <i>Seminars in Hematology</i> , 2015 , 52, 46-52	4	21
205	Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. <i>British Journal of Haematology</i> , 2013 , 162, 693-701	4.5	21
204	Stability of measurement of the immature platelet fraction. <i>American Journal of Hematology</i> , 2010 , 85, 622-4	7.1	21
203	Differential diagnosis and management of thrombocytopenia in childhood. <i>Pediatric Clinics of North America</i> , 2004 , 51, 1109-40, xi	3.6	21
202	Fetal and neonatal alloimmune thrombocytopenia in pregnancies involving in vitro fertilization: a report of four cases. <i>American Journal of Obstetrics and Gynecology</i> , 2005 , 192, 543-7	6.4	21
201	Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): Impact of ITP on health-related quality of life. <i>American Journal of Hematology</i> , 2021 , 96, 199-207	7.1	21
200	A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). <i>Blood</i> , 2007 , 109, 5527; author reply 5528	2.2	20
199	Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim. <i>Hematology</i> , 2016 , 21, 257-62	2.2	19
198	Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone. <i>Journal of Pediatrics</i> , 2017 , 191, 225-231	3.6	19
197	Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. <i>British Journal of Haematology</i> , 2012 , 158, 811-4	4.5	19

196	Th1 and Th2 cytokines in a patient with Evans Syndrome and profound lymphopenia. <i>British Journal of Haematology</i> , 2000 , 110, 968-70	4.5	19
195	Intravenous immune serum globulin in immune thrombocytopenia: clinical results and biochemical evaluation. <i>Vox Sanguinis</i> , 1985 , 49 Suppl 1, 44-50	3.1	19
194	Fc receptors in immune thrombocytopenias: a target for immunomodulation?. <i>Journal of Clinical Investigation</i> , 2008 , 118, 2677-81	15.9	19
193	Novel thrombopoietic agents. <i>Hematology American Society of Hematology Education Program</i> , 2007 , 2007, 106-13	3.1	18
192	The in utero diagnosis and management of alloimmune thrombocytopenia. <i>Prenatal Diagnosis</i> , 1988 , 8, 329-31	3.2	18
191	Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. <i>Blood</i> , 2020 , 136, 3056-3061	2.2	18
190	Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. <i>Rheumatology</i> , 2018 , 57, 1432-1438	3.9	17
189	Thrombocytopenia with absent radii: frequency of marrow megakaryocyte progenitors, proliferative characteristics, and megakaryocyte growth and development factor responsiveness. <i>Pediatric Hematology and Oncology</i> , 2000 , 17, 299-306	1.7	17
188	Favorable neurological outcome in 7 cases of perinatal intracranial hemorrhage due to immune thrombocytopenia. <i>Journal of Pediatric Hematology/Oncology</i> , 1991 , 13, 156-9	1.2	17
187	Review of fetal and neonatal immune cytopenias. <i>Clinical Advances in Hematology and Oncology</i> , 2015 , 13, 35-43	0.6	17
186	The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP). <i>British Journal of Haematology</i> , 2013 , 160, 237-43	4.5	16
185	High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2002 , 118, 836-8	4.5	16
184	Splenectomy-sparing strategies for the treatment and long-term maintenance of chronic idiopathic (immune) thrombocytopenic purpura. <i>Seminars in Hematology</i> , 2000 , 37, 1-4	4	15
183	Serum levels of GM-CSF are elevated in patients with thrombocytopenia. <i>British Journal of Haematology</i> , 1996 , 92, 486-8	4.5	15
182	Screening for Wiskott-Aldrich syndrome by flow cytometry. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 142, 333-335.e8	11.5	15
181	Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. <i>Seminars in Hematology</i> , 2019 , 56, 262-278	4	14
180	Accurate intrapartum estimation of fetal platelet count by fetal scalp samples smear. <i>American Journal of Perinatology</i> , 1994 , 11, 42-5	3.3	14
179	Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.. <i>Blood</i> , 2006 , 108, 476-476	2.2	14

178	Long Term Follow-Up of Patients with Immune Thrombocytopenic Purpura (ITP) Whose Initial Response to Rituximab Lasted a Minimum of 1 Year.. <i>Blood</i> , 2006 , 108, 479-479	2.2	14
177	Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE). <i>Blood</i> , 2008 , 112, 400-400	2.2	14
176	Alloimmune thrombocytopenia. <i>Clinical Obstetrics and Gynecology</i> , 1999 , 42, 335-48	1.7	14
175	Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020 , 190, 933-938	4.5	14
174	Thrombopoietic agents in immune thrombocytopenia. <i>Seminars in Hematology</i> , 2010 , 47, 258-65	4	13
173	Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor. <i>British Journal of Haematology</i> , 2016 , 173, 942-5	4.5	13
172	Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study. <i>American Journal of Hematology</i> , 2019 , 94, 200-208	7.1	13
171	Superior effect of intravenous anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison. <i>American Journal of Hematology</i> , 2007 , 82, 335-41	7.1	12
170	New therapies for immune thrombocytopenic purpura. <i>Current Opinion in Hematology</i> , 2007 , 14, 427-31	3.3	12
169	Successful Discontinuation of Eltrombopag Treatment in Patients with Chronic ITP. <i>Blood</i> , 2012 , 120, 1085-1085	2.2	12
168	Platelet transfusion practices in immune thrombocytopenia related hospitalizations. <i>Transfusion</i> , 2019 , 59, 169-176	2.9	12
167	Postnatal intervention for the treatment of FNAIT: a systematic review. <i>Journal of Perinatology</i> , 2019 , 39, 1329-1339	3.1	11
166	Hospitalizations in pediatric patients with immune thrombocytopenia in the United States. <i>Platelets</i> , 2016 , 27, 472-8	3.6	11
165	Suppression of in vitro megakaryopoiesis by maternal sera containing anti-HPA-1a antibodies. <i>Blood</i> , 2015 , 126, 1234-6	2.2	11
164	Therapeutic approaches to secondary immune thrombocytopenic purpura. <i>Seminars in Hematology</i> , 2009 , 46, S44-58	4	11
163	The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia. <i>Current Opinion in Oncology</i> , 2008 , 20, 690-6	4.2	11
162	Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor.. <i>Blood</i> , 2006 , 108, 475-475	2.2	11
161	Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists. <i>Thrombosis Research</i> , 2020 , 185, 119-124	8.2	11

160	Omission of fetal sampling in treatment of subsequent pregnancies in fetal-neonatal alloimmune thrombocytopenia. <i>American Journal of Obstetrics and Gynecology</i> , 2016 , 215, 471.e1-9	6.4	11
159	Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists. <i>Platelets</i> , 2020 , 31, 198-205	3.6	11
158	Health-related quality of life in adult primary immune thrombocytopenia. <i>Expert Review of Hematology</i> , 2018 , 11, 975-985	2.8	11
157	Eltrombopag. <i>Cancer Treatment and Research</i> , 2011 , 157, 289-303	3.5	11
156	Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2007 , 82, 192-8	7.1	10
155	3G8 and GMA161, Anti Fc β III Inhibitory Monoclonal Antibodies in the Treatment of Chronic Refractory ITP. (Summary of 2 Pilot Studies).. <i>Blood</i> , 2009 , 114, 2404-2404	2.2	10
154	Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation. <i>Haematologica</i> , 2016 , 101, e237-9	6.6	10
153	SARS-CoV-2 Vaccination and Immune Thrombocytopenia in de novo and pre-existing ITP patients. <i>Blood</i> , 2021 ,	2.2	10
152	Fatigue in children and adolescents with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020 , 191, 98-106	4.5	9
151	Imaging and management of fetuses and neonates with alloimmune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2017 , 64, e26690	3	9
150	Patients with Immune Thrombocytopenia (ITP) Frequently Experience Severe Fatigue but Is It Under-Recognized By Physicians: Results from the ITP World Impact Survey (I-WISH). <i>Blood</i> , 2018 , 132, 2273-2273	2.2	9
149	Hyper-Sialylated IgG M254, an Innovative Therapeutic Candidate, Evaluated in Healthy Volunteers and in Patients with Immune Thrombocytopenia Purpura: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics. <i>Blood</i> , 2019 , 134, 1090-1090	2.2	9
148	COVID-19 vaccination and immune thrombocytopenia. <i>Nature Medicine</i> , 2021 , 27, 1145-1146	50.5	9
147	Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia. <i>Platelets</i> , 2019 , 30, 206-212	3.6	9
146	Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib. <i>Therapeutic Advances in Hematology</i> , 2021 , 12, 20406207211010875	5.7	9
145	Update on eltrombopag for ITP. <i>Oncology</i> , 2009 , 23, 1177-8	1.8	9
144	Overview of thrombopoietic agents in the treatment of thrombocytopenia. <i>Clinical Lymphoma and Myeloma</i> , 2008 , 8, 33-43		8
143	Therapy in cytopenia. <i>Vox Sanguinis</i> , 1986 , 51 Suppl 2, 69-73	3.1	8

142	Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study. <i>British Journal of Haematology</i> , 2019 , 185, 102-106	4.5	8
141	Strategies to develop a prophylaxis for the prevention of HPA-1a immunization and fetal and neonatal alloimmune thrombocytopenia. <i>Transfusion and Apheresis Science</i> , 2020 , 59, 102712	2.4	7
140	Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2019 , 185, 136-139	4.5	7
139	Thrombopoietic agents: there is still much to learn. <i>Presse Medicale</i> , 2014 , 43, e69-78	2.2	7
138	A Review of Romiplostim Mechanism of Action and Clinical Applicability. <i>Drug Design, Development and Therapy</i> , 2021 , 15, 2243-2268	4.4	7
137	Prognostic relevance of large-platelet counts in patients with immune thrombocytopenic purpura. <i>Haematologica</i> , 2005 , 90, 1715-6	6.6	7
136	Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and children. <i>British Journal of Haematology</i> , 2020 , 189, e37-e40	4.5	6
135	The new thrombopoietic agenda: impact on leukemias and MDS. <i>Best Practice and Research in Clinical Haematology</i> , 2014 , 27, 288-92	4.2	6
134	Long-Term Treatment of Chronic Immune Thrombocytopenic Purpura with Oral Eltrombopag: Results From the EXTEND Study.. <i>Blood</i> , 2009 , 114, 682-682	2.2	6
133	Self-administration of romiplostim in patients with chronic immune thrombocytopenia. <i>Community Oncology</i> , 2013 , 10, 285-292		6
132	Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia. <i>Haematologica</i> , 2016 , 101, 1327-1332	6.6	6
131	Another interaction of the FcR system with IVIG. <i>Thrombosis and Haemostasis</i> , 2002 , 88, 890-1	7	6
130	Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treat. <i>Hematology/Oncology Clinics of North America</i> , 2009 , 23, 1329-41	3.1	5
129	Fetal and neonatal cytopenias: what have we learned?. <i>American Journal of Perinatology</i> , 2003 , 20, 425-33.3		5
128	Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP). <i>Blood</i> , 2019 , 134, 1095-1095	2.2	5
127	Evaluation of AMG 531 Efficacy in Nonsplenectomized Patients with Chronic Immune Thrombocytopenic Purpura (ITP) in a Randomized Placebo-Controlled Phase 3 Study.. <i>Blood</i> , 2007 , 110, 565-565	2.2	5
126	Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases,. <i>Blood</i> , 2011 , 118, 3281-3281	2.2	5
125	Update On The Safety and Efficacy Of EXTENDED Treatment With Eltrombopag (EPAG) In Adults With Chronic Immune Thrombocytopenia (ITP). <i>Blood</i> , 2013 , 122, 2315-2315	2.2	5

124	Thrombopoietin Receptor Agonists in Paediatric ITP Patients: Long Term Follow up Data in 34 Patients. <i>Blood</i> , 2014 , 124, 4206-4206	2.2	5
123	New developments in fetal and neonatal alloimmune thrombocytopenia. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 225, 120-127	6.4	5
122	Peri- and Postpartum Management of Patients With Factor XI Deficiency. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019 , 25, 1076029619880262	3.3	4
121	Immune Thrombocytopenia (ITP) 2013 , 819-833		4
120	TPO for ITP in pregnancy. <i>Blood</i> , 2017 , 130, 1073-1074	2.2	4
119	Identifying babies with neonatal alloimmune thrombocytopenia and the responsible antigens. <i>Transfusion</i> , 2007 , 47, 6-7	2.9	4
118	Is it necessary to test patients with immune thrombocytopenic purpura (ITP) for seropositivity to HTLV-1?. <i>American Journal of Hematology</i> , 1999 , 61, 94-7	7.1	4
117	Results from the ITP World IMPACT Survey (I-WISH): Patients with Immune Thrombocytopenia (ITP) Experience Impaired Quality of Life (QoL) Regarding Daily Activities, Social Interactions, Emotional Well-Being and Working Lives. <i>Blood</i> , 2018 , 132, 4804-4804	2.2	4
116	Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia. <i>Blood</i> , 2019 , 134, 897-897	2.2	4
115	GMA161 Treatment of Refractory ITP: Efficacy of FcγRIII Blockade.. <i>Blood</i> , 2006 , 108, 1074-1074	2.2	4
114	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. <i>Blood</i> , 2015 , 126, 73-73	2.2	4
113	Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome. <i>Blood Advances</i> , 2020 , 4, 3368-3377	7.8	4
112	Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia. <i>Transfusion</i> , 2016 , 56, 2449-2454	2.9	4
111	Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists. <i>Platelets</i> , 2020 , 31, 322-328	3.6	4
110	Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia. <i>Haematologica</i> , 2020 , 105, e129-e132	6.6	4
109	FAS mutations are an uncommon cause of immune thrombocytopenia in children and adults without additional features of immunodeficiency. <i>British Journal of Haematology</i> , 2019 , 186, e163-e165	4.5	3
108	Maternal sensitization occurs before delivery in severe cases of fetal alloimmune thrombocytopenia. <i>American Journal of Hematology</i> , 2019 , 94, E213-E215	7.1	3
107	Platelet count control in immune thrombocytopenic purpura patient: Optimum romiplostim dose profile. <i>Journal of Process Control</i> , 2016 , 45, 76-83	3.9	3

106	Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP). <i>Platelets</i> , 2017 , 28, 478-483	3.6	3
105	Predictors of Remission in Adults with Immune Thrombocytopenia Treated with Romiplostim. <i>Blood</i> , 2018 , 132, 735-735	2.2	3
104	Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia. <i>Blood</i> , 2019 , 134, 4889-4889	2.2	3
103	Insights into Therapeutic Mechanisms: Measuring Immature Platelet Fraction (IPF) Describes Response to Treatment in Immune Thrombocytopenic Purpura (ITP).. <i>Blood</i> , 2006 , 108, 1070-1070	2.2	3
102	Safety and Efficacy Of Eltrombopag At Escalated Doses Up To 150mg In Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Not Responsive To 75 Mg. <i>Blood</i> , 2013 , 122, 3559-3559	2.2	3
101	PETIT and PETIT 2: Treatment with Eltrombopag in 171 Children with Chronic Immune Thrombocytopenia (ITP). <i>Blood</i> , 2014 , 124, 1450-1450	2.2	3
100	Efficacy of Eltrombopag in Adult East Asian and Non-East Asian Patients with Chronic Immune Thrombocytopenia (cITP): Results from the Extend Study. <i>Blood</i> , 2016 , 128, 4930-4930	2.2	3
99	Identification of occult cerebral microbleeds in adults with immune thrombocytopenia. <i>Blood</i> , 2020 , 136, 2875-2880	2.2	3
98	A pilot study of rhuIL-11 treatment of refractory ITP 2001 , 66, 172		3
97	Platelet count control in immune thrombocytopenic purpura patient: optimum romiplostim dose profile. <i>IFAC Postprint Volumes IPPV / International Federation of Automatic Control</i> , 2014 , 47, 11800-11805		2
96	Modified antibody in fetal alloimmunization. <i>Blood</i> , 2013 , 122, 303-4	2.2	2
95	The changing landscape of secondary ITP: introduction. <i>Seminars in Hematology</i> , 2009 , 46, S1	4	2
94	How effective is eltrombopag for the treatment of thrombocytopenia in patients with HCV infection?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008 , 5, 424-5		2
93	Immune Thrombocytopenic Purpura 2007 , 831-845		2
92	Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients. <i>Blood</i> , 2019 , 134, 1069-1069	2.2	2
91	The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey. <i>Blood</i> , 2019 , 134, 1076-1076	2.2	2
90	Response to Treatment of Helicobacter Pylori in Patients with Immune Thromboctypenic Purpura: A Systematic Review and Metaanalysis.. <i>Blood</i> , 2005 , 106, 2151-2151	2.2	2
89	R935788: A Phase II, Single Center, Open Label, Efficacy and Safety, Ascending Dose, Pilot Study for the Treatment of Adult Immune Thrombocytopenic Purpura (ITP).. <i>Blood</i> , 2007 , 110, 1310-1310	2.2	2

88	Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP).. <i>Blood</i> , 2009 , 114, 1322-1322	2.2	2
87	A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim in Children with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP).. <i>Blood</i> , 2009 , 114, 680-680	2.2	2
86	Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.. <i>Blood</i> , 2009 , 114, 681-681	2.2	2
85	Platelet Function and Response to Thrombopoietin Mimetics In Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia.. <i>Blood</i> , 2010 , 116, 1429-1429	2.2	2
84	Hepatobiliary and Thromboembolic Events during Long-Term E.X.T.E.N.Ded Treatment with Eltrombopag in Adult Patients with Chronic Immune Thrombocytopenia (ITP). <i>Blood</i> , 2016 , 128, 1368-1368	2.2	2
83	Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long-Term, Open-Label Extend Study. <i>Blood</i> , 2016 , 128, 3742-3742	2.2	2
82	LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia. <i>Blood</i> , 2021 , 138, 1010-1010	2.2	2
81	Intravenous Immunoglobulin Manufactured Using a Novel Caprylate and Chromatography-Based Method (IGIV-C, Gamunex [®]) Was Safe and Well Tolerated When Administered at an Increased Maximum Rate in Patients with Idiopathic Thrombocytopenic Purpura (ITP).. <i>Blood</i> , 2004 , 104, 3027-3027	2.2	2
80	Mental Health and Treatment in Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry. <i>Blood</i> , 2019 , 134, 2362-2362	2.2	2
79	Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP). <i>British Journal of Haematology</i> , 2020 , 189, 379-382	4.5	2
78	Immune thrombocytopenia during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2021 , 193, 1093-1095	4.5	2
77	IVIg and Fc γ RIIb in kids with ITP: individualizing therapy. <i>Blood</i> , 2018 , 132, 877-878	2.2	2
76	Novel thrombopoietic agents: preliminary activity, potential benefit. <i>The Journal of Supportive Oncology</i> , 2007 , 5, 63-84		2
75	Response to thrombopoietic agents is related to on-treatment bone marrow megakaryocyte morphology in patients with chronic immune thrombocytopenia. <i>American Journal of Hematology</i> , 2019 , 94, E196-E198	7.1	1
74	Immune Thrombocytopenia (ITP) 2019 , 707-724		1
73	Fetal and Neonatal Alloimmune Thrombocytopenia 2013 , 609-613		1
72	When are platelets just platelets?. <i>Blood</i> , 2006 , 107, 3426-3427	2.2	1
71	Standard Dose Rituximab Plus 2 \times Cycles of Pulse Dexamethasone Is Effective and Tolerable in Treatment of Immune Thrombocytopenia (ITP). <i>Blood</i> , 2011 , 118, 1166-1166	2.2	1

70	Cumulative Response to Eltrombopag and Impact of the Number of Prior ITP Therapies: Interim Results of a Long-Term Extension Study,. <i>Blood</i> , 2011 , 118, 3297-3297	2.2	1
69	Response to TPO-Receptor Agonists: Role of Immature Platelet Fraction and Anti-GP1b. <i>Blood</i> , 2014 , 124, 4190-4190	2.2	1
68	Surveillance Program of Romiplostim Use Connected to Pregnancy. <i>Blood</i> , 2021 , 138, 585-585	2.2	1
67	COVID-19 Vaccination in Adults with Immune Thrombocytopenia (ITP): Data from the Platelet Disorder Support Association (PDSA) Patient Registry. <i>Blood</i> , 2021 , 138, 3164-3164	2.2	1
66	Splenectomized Patients Have Reduced CD27+ Memory B Cells but Protective Antibody Responses to Pneumococcal Vaccination.. <i>Blood</i> , 2004 , 104, 3025-3025	2.2	1
65	Re-Treatment with Rituximab in ITP: Comparison of Standard Dose with 2 Forms of Augmented Rituximab.. <i>Blood</i> , 2005 , 106, 1237-1237	2.2	1
64	Health Related Quality of Life and Fatigue Improve on Second Line Treatments in Pediatric Immune Thrombocytopenia (ITP). <i>Blood</i> , 2017 , 130, 752-752	2.2	1
63	Immune thrombocytopenia. <i>Expert Review of Hematology</i> , 2021 , 1-13	2.8	1
62	Classical Pathway of Complement Activation in ITP: Inhibition By TNT003, a Novel C1s Inhibitor. <i>Blood</i> , 2014 , 124, 1453-1453	2.2	1
61	Survey of the Side Effects of ITP Therapies. <i>Blood</i> , 2012 , 120, 3327-3327	2.2	1
60	Immune Thrombocytopenia: A Complex Autoimmune Disease 2020 , 911-921		1
59	Preparing patients with immune thrombocytopenia for surgery: what are the options?. <i>Lancet Haematology,the</i> , 2020 , 7, e626-e627	14.6	1
58	Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e29023	3	1
57	Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients. <i>ELife</i> , 2021 , 10,	8.9	1
56	Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists. <i>American Journal of Hematology</i> , 2021 , 96, E373-E376	7.1	1
55	Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2019 , 41, e257-e259	1.2	1
54	Fetal and Neonatal Alloimmune Thrombocytopenia 2019 , 581-588		1
53	Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment. <i>Platelets</i> , 2019 , 30, 222-228	3.6	1

52	TPO-mimetics for chemotherapy-induced thrombocytopenia: timing matters. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2763-2764	1.9	1
51	Familial thrombocythaemia - a distinct entity from essential thrombocythaemia. <i>British Journal of Haematology</i> , 2021 , 194, 808-809	4.5	1
50	Absence of Plasma Gastric Biomarker Elevations with Chronic Dosing of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Patients with Chronic Immune Thrombocytopenia in Phase 3 Trials. <i>Blood</i> , 2018 , 132, 3740-3740	2.2	0
49	Safety and Efficacy of the Off-Label Use of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia in Pregnancy: Results from a Multicentre Observational Study. <i>Blood</i> , 2019 , 134, 1081-1081 ^{2,3}	2.2	0
48	Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study). <i>Blood</i> , 2021 , 138, 2088-2088	2.2	0
47	Splenectomy Results in Venous Thromboembolic Events in Women: A Nurses Health Study. <i>Blood</i> , 2021 , 138, 3163-3163	2.2	0
46	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. <i>Blood</i> , 2021 , 138, 586-586	2.2	0
45	Standard Dose Rituximab and 3 4-Day Cycles of Dexamethasone (R+3D) Appears Curative in Females with ITP <i>Blood</i> , 2015 , 126, 1059-1059	2.2	0
44	Disorders of Platelets 2016 , 239-278		0
43	Hemolysis after High-Dose Intravenous Immunoglobulin: an Under-Appreciated Sequelae.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0
42	Immune Thrombocytopenia: Where Are We Now? 2017 , 749-760		
41	Fetal and neonatal immune thrombocytopenia 141-156		
40	Eltrombopag for chronic immune thrombocytopenia [AuthorsPreply. <i>Lancet, The</i> , 2011 , 377, 1919-1920	4.0	
39	IVIg in ITP: no role for cytokines?. <i>Blood</i> , 2007 , 109, 4-5	2.2	
38	Review of therapies for immune thrombocytopenic purpura. <i>Seminars in Hematology</i> , 2006 , 43, S1-2	4	
37	Thrombocytopenia 2001 , 155-185		
36	The Treatment of Patients with Autoimmune Thrombocytopenia with Intravenous IgG-Anti-D. <i>Vox Sanguinis</i> , 1999 , 76, 252-252	3.1	
35	ITP World Impact Survey (I-WISH) 2.0: Further Exploration of the Impact of ITP on Patients. <i>Blood</i> , 2020 , 136, 2-3	2.2	

- 34 Clinical Outcomes in Patients with Immune Thrombocytopenia Treated with All 3 Approved Thrombopoietin Receptor Agonists. *Blood*, **2020**, 136, 18-19 2.2
- 33 Disorders of platelets **2022**, 237-285
- 32 Do Splenectomized Immune Thrombocytopenia (ITP) Patients Have Increased Risks for Platelet Decreases Following COVID-19 Vaccination?. *Blood*, **2021**, 138, 2090-2090 2.2
- 31 Alloimmune thrombocytopenia **2002**, 569-583
- 30 Assessment of Bleeding in Thrombocytopenic Patients (pts) with Immune Thrombocytopenic Purpura (ITP).. *Blood*, **2005**, 106, 1255-1255 2.2
- 29 Velocardiofacial Syndrome (VCF): Presentation with and Management of Immune Cytopenias.. *Blood*, **2006**, 108, 3986-3986 2.2
- 28 Development and Initial Validation of the Immune Thrombocytopenic Purpura Patient Assessment Questionnaire (ITP-PAQ), a Disease-Specific Health-Related Quality of Life (HRQoL) Questionnaire.. *Blood*, **2006**, 108, 1078-1078 2.2
- 27 Defective Circulating CD25 Regulatory T Cells in Patients with Chronic Immune Thrombocytopenic Purpura.. *Blood*, **2007**, 110, 570-570 2.2
- 26 Two placebo-controlled phase 3 studies of fostamatinib, an oral spleen tyrosine kinase (Syk) inhibitor, for the treatment of persistent/chronic immune thrombocytopenia (ITP) in adults: Analysis of platelet response by prior ITP therapies.. *Journal of Clinical Oncology*, **2018**, 36, e15146-e15146 2.2
- 25 Thrombin-Generating Capacity of Microvesicles (MVs) in Patients with Immune Thrombocytopenia (ITP) before and during Treatment with Thrombopoietin-Receptor Agonists (TPO-RA). *Blood*, **2018**, 132, 2511-2511 2.2
- 24 Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in Patients Who Did and Did Not Receive Prior Rituximab (Ritux): A Post-Hoc Analysis of the Extend Study. *Blood*, **2018**, 132, 1152-1152 2.2
- 23 Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Guidance to Reduce the Risk of Intracranial Bleeding. *Blood*, **2018**, 132, 4717-4717 2.2
- 22 Medical Decision Analysis: Choosing Second Line Treatment in Adults with Immune Thrombocytopenia (ITP). *Blood*, **2018**, 132, 4986-4986 2.2
- 21 Immune Thrombocytopenia: Are We Stuck in the Mud or Is There Light at the End of the Tunnel?. *Clinical Hematology International*, **2019**, 1, 173-179 1.8
- 20 Physicians and Patients' Perspectives on Treatments in ITP - a Multi-Country Perspective: Results from the ITP World Impact Survey (I-WISH). *Blood*, **2019**, 134, 1097-1097 2.2
- 19 Safety and Efficacy of Long-Term Open-Label Dosing of Romiplostim in Thrombocytopenic Pediatric Patients (Pts) with Immune Thrombocytopenia (ITP). *Blood*, **2014**, 124, 4184-4184 2.2
- 18 Issues in Categorization and Management of Pediatric Patients with Myeloproliferative Neoplasms. *Blood*, **2014**, 124, 1843-1843 2.2
- 17 Enhanced Megakaryocyte Apoptosis Corresponds to Higher Platelet Counts in Immune Thrombocytopenia Patients and Increased Proplatelet Formation in Cell Culture. *Blood*, **2014**, 124, 5114-5114 2.2

16	Effects of Thrombopoietin Mimetics on Patients with Chronic ITP: Perspectives from Blood Transcriptome Profiling Analysis. <i>Blood</i> , 2014 , 124, 2780-2780	2.2
15	Clinical Features of Alloimmune Neutropenia: Composite of 2 Case Series and 39 Case Reports. <i>Blood</i> , 2015 , 126, 4607-4607	2.2
14	Effects of Anti-Glycoprotein Antibodies on Response of Immune Thrombocytopenia Patients to Thrombopoietin Receptor Agonists and on Megakaryocytes Viability. <i>Blood</i> , 2015 , 126, 1048-1048	2.2
13	Self-Injection of Romiplostim by Patients with Chronic Immune Thrombocytopenic Purpura (ITP). <i>Blood</i> , 2008 , 112, 4707-4707	2.2
12	Association Between IgA Immunoglobulin Level and Response to Treatment for Immune Thrombocytopenia (ITP).. <i>Blood</i> , 2009 , 114, 3503-3503	2.2
11	Time to Splenectomy Failure in Patients with Recurrent or Refractory Chronic Immune Thrombocytopenic Purpura.. <i>Blood</i> , 2009 , 114, 3522-3522	2.2
10	The Effect of Eltrombopag on Human Platelet Resistance to Apoptosis: The Role of the Bcl-Xl Pathway. <i>Blood</i> , 2010 , 116, 2520-2520	2.2
9	The Use of Immature Platelet Fraction to Assess Thrombopoiesis and Mechanisms of Treatment Effect In Immune Thrombocytopenia (ITP). <i>Blood</i> , 2010 , 116, 2513-2513	2.2
8	Rituximab Maintenance Treatment In Immune Mediated Thrombocytopenia (ITP) Including Evans Syndrome. <i>Blood</i> , 2010 , 116, 2523-2523	2.2
7	Dynamics of Improvement in Health-Related Quality of Life (HRQoL) with Long-Term Eltrombopag Treatment in Adults with Chronic Immune Thrombocytopenia (ITP) in EXTEND.. <i>Blood</i> , 2012 , 120, 2199-2199	2.2
6	Cyclosporine-Romiplostim-IVIG Combination Therapy In Patients With Severe Immune Thrombocytopenia (ITP). <i>Blood</i> , 2013 , 122, 1085-1085	2.2
5	Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP). <i>Blood</i> , 2013 , 122, 3530-3530	2.2
4	Early combination treatment of immune thrombocytopenia: Is this the way?. <i>American Journal of Hematology</i> , 2020 , 95, 1452-1453	7.1
3	Fetal and Neonatal Alloimmune Thrombocytopenias 2021 , 223-242	
2	Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study. <i>British Journal of Haematology</i> , 2021 ,	4.5
1	Heritable platelet disorders: an enigma even guidelines can't unravel. <i>British Journal of Haematology</i> , 2021 , 195, 13-14	4.5